Urologic Neoplasms

• EMA approval · 2026-08-19
  EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG

  European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…

• EMA approval · 2026-07-29
  EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.

  EMA authorizes Padcev (enfortumab vedotin) for specified urologic carcinoma indications, marking an official market approval.

• EMA approval · 2026-07-22
  EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.

  The EMA authorised Padcev (enfortumab vedotin) for indicated urologic cancers, marking a new approval by Astellas Pharma Europe B.V.

• EMA approval · 2026-07-21
  EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH

  Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…

• EMA approval · 2026-07-01
  EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.

  EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-04-28
  EMA Authorised: Balversa (Erdafitinib) — Janssen-Cilag International N.V.

  Authorised status for Balversa (Erdafitinib) by EMA for urologic neoplasms.

• EMA approval · 2026-04-28
  EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH

  Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.